GH Jan 2025 22.500 put
| Previous Close | 2.5000 |
| Open | 2.5000 |
| Bid | 1.9500 |
| Ask | 2.2500 |
| Strike | 22.50 |
| Expire Date | 2025-01-17 |
| Day's Range | 2.5000 - 2.5000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 261 |
Simply Wall St.Even after rising 7.4% this past week, Guardant Health (NASDAQ:GH) shareholders are still down 74% over the past three years
It is doubtless a positive to see that the Guardant Health, Inc. ( NASDAQ:GH ) share price has gained some 58% in the...
Business WireGuardant Health introduces new Guardant360 TissueNext test with nearly 500 biomarkers to identify more treatment options for patients with advanced cancer
PALO ALTO, Calif., June 04, 2024--Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the launch of a new version of its Guardant360 TissueNext test that expands the number of genes it identifies in a tumor tissue sample to 498. These genes, or cancer biomarkers, enable oncologists to identify the targeted therapies or treatment strategies that are most effective for patients with advanced cancer. In addition to the panel expansion, Guardant has improved the
Business WireGuardant Health and Washington University to present study at 2024 ASCO meeting highlighting utility of ctDNA to address racial inequities in the use of targeted therapies and enrollment in clinical trials
PALO ALTO, Calif., June 03, 2024--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced its research collaborators from Washington University’s Siteman Cancer Center will lead an oral presentation today at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting highlighting the potential role of liquid biopsy in addressing racial inequities in enrollment in clinical trials and in the use of targeted therapies for advanced breast cancer.
